Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Artiva Biotherapeutics, Inc. (ARTV) had Stock-Based Compensation of $6.82M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-83.86M |
|
-- |
|
-- |
|
$89.81M |
|
$-89.81M |
|
$5.95M |
|
$-83.86M |
|
$-83.86M |
|
$-83.86M |
|
$-83.86M |
|
$-83.86M |
|
$-83.86M |
|
$-89.81M |
|
$-87.21M |
|
24.44M |
|
24.44M |
|
$-3.43 |
|
$-3.43 |
|
| Balance Sheet Financials | |
$112.67M |
|
$6.62M |
|
$18.27M |
|
$130.94M |
|
$13.09M |
|
-- |
|
$7.88M |
|
$20.97M |
|
$109.97M |
|
$109.97M |
|
$109.97M |
|
24.60M |
|
| Cash Flow Statement Financials | |
$-76.75M |
|
$63.41M |
|
$0.01M |
|
$40.49M |
|
$27.16M |
|
$-13.33M |
|
|
Stock-Based Compensation |
$6.82M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.61 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-79.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-76.26% |
|
-76.26% |
|
-64.05% |
|
-76.26% |
|
$4.47 |
|
$-3.25 |
|
$-3.14 |
|